In Brief: Selfcare
This article was originally published in The Tan Sheet
Executive Summary
Selfcare: Completes initial public offering of 1.3 mil. shares at $8.50 a share, the firm announces Aug. 6. The Waltham, Mass.-based maker of "self-test" diagnostics for diabetes, women's health and infectious diseases plans to use the proceeds for R&D, working capital and "other general corporate purposes, including the possible repayment of certain indebtedness and possible acquisitions," the firm states. In a registration statement for the offering, filed with the Securities and Exchange Commission in May, Selfcare projected offering 2.7 mil. shares for $12 each ("The Tan Sheet" June 17, p. 14). The issue trades on the American Stock Exchange under the symbol "SLF"...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning